Definium Therapeutics US, Inc.
8 clinical trials · Sponsor
◉ Watch Definium Therapeutics US, Inc.
| Record | Firm | Date |
|---|---|---|
| A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend) (NCT07592689) | Definium Therapeutics US, Inc. | 2026-05-10 |
| A Phase 2A Trial of DT402 for Autism Spectrum Disorder (NCT07303907) | Definium Therapeutics US, Inc. | 2025-12-03 |
| A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge) (NCT06941844) | Definium Therapeutics US, Inc. | 2025-04-14 |
| A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage) (NCT06741228) | Definium Therapeutics US, Inc. | 2024-12-11 |
| A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms (NCT05407064) | Definium Therapeutics US, Inc. | 2022-08-24 |
| Safety and Efficacy of Low Dose MM120 for ADHD Proof of Concept Trial (NCT05200936) | Definium Therapeutics US, Inc. | 2021-12-17 |
| A Study to Assess 18-Methoxycoronaridine (18-MC HCl) in Healthy Volunteers (NCT04292197) | Definium Therapeutics US, Inc. | 2020-04-14 |
Track Definium Therapeutics US, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.